Hypersensitivity reactions to biologics in children

References

• Niehues T, Özgür TT. The efficacy and evidence-based use of biologics in children and adolescents: using monoclonal antibodies and fusion proteins as treatments. Dtsch Arztebl Int. 2019;116(42):703–710.
   Web of Science ®Google Scholar
• Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159–170.e2.
   PubMed Web of Science ®Google Scholar
• Esenboga S, Akarsu A, Ocak M, et al. Safety and efficacy of rapid drug desensitization in children. Pediatr Allergy Immunol off Publ Eur Soc Pediatr Allergy Immunol. 2022;33:e13759.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
   PubMed Web of Science ®Google Scholar
• Marino A, Real-Fernández F, Rovero P, et al. Anti-Adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37:1407–1411.
   PubMed Web of Science ®Google Scholar
• Yilmaz Topal O, Kose V, Acar B, et al. Evaluation of hypersensitivity reactions in pediatric patients using biological drugs. Int Arch Allergy Immunol. 2021;182:844–851.
   PubMed Web of Science ®Google Scholar
• Mori F, Saretta F, Bianchi A, et al. Hypersensitivity reactions to monoclonal antibodies in children. Med. 2020;56:1–23.
   Google Scholar
• Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259–1266.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Expert Committee on Biological Standardization. Sixty-fifth report. World Health Organ Tech Rep Ser. 2015;993:1–262.
   Web of Science ®Google Scholar
• Rossi F, Cuomo V, Riccardi C . Farmacologia - Principi di base e applicazioni terapeutiche. III. Torino: Edizioni Minerva Medica SPA; 2017.
   Google Scholar
• Liu XI, Dallmann A, Wang Y, et al. Monoclonal antibodies and fc‐fusion proteins for pediatric use: dosing, immunogenicity, and modeling and simulation in data submitted to the us food and drug administration. J Clin Pharmacol. 2019;59:1130–1143.
   PubMed Web of Science ®Google Scholar
• Levy G. Pharmacologic target‐mediated drug disposition. Clin Pharmacol Ther. 1994;56:248‐252.
   Web of Science ®Google Scholar
• Vultaggio A, Petroni G, Pratesi S, et al. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin Exp Immunol. 2016;186:364–372.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy Eur J Allergy Clin Immunol. 2010;65:657–661.
   Google Scholar
• Vultaggio A, Nencini F, Bormioli S, et al. Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reaction. J Allergy Clin Immunol Pract. 2020;8:1764–1767.e1.
   PubMed Web of Science ®Google Scholar
• Gruchalla RS; Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol. 2003;111:S548–59.
   PubMedGoogle Scholar
• Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55–63.
   PubMed Web of Science ®Google Scholar
• Rajan TV. The Gell–Coombs classification of hypersensitivity reactions: a re-interpretation. TRENDS Immunol. 2003;24:376–379.
   PubMed Web of Science ®Google Scholar
• Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5:600–609.
   PubMed Web of Science ®Google Scholar
• Baldo, Brian A, Pham, Nghia H.Drug allergy. Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York Springer; 2013.
   Google Scholar
• de las Vecillas L, Castells M. Non-IgE adverse reactions to biologics. J Allergy Clin Immunol. 2020;4:6–8.
   Google Scholar
• Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 2014;24:212–225.
   PubMed Web of Science ®Google Scholar
• Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum 2015;45:334–340.
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725–732.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Alvarez-Cuesta E, Broyles AD, et al. Standards for practical intravenous rapid drug desensitization & delabeling: a WAO committee statement. World Allergy Organ J 2022;15(6):100640.
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224.
   PubMed Web of Science ®Google Scholar
• Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des. 2008;14:2883–2891.
   PubMed Web of Science ®Google Scholar
• El-Matary W, Dykes DMH, Bauman L, et al. Rapid infliximab infusion in children with inflammatory bowel disease: a multicenter north American experience. Inflamm Bowel Dis. 2017;23(12):2104–2108.
   PubMed Web of Science ®Google Scholar
• KG BEM, Koretzky GA. Cytokine Storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 2017;69(6):1135–1143.
   PubMed Web of Science ®Google Scholar
• Milosevits G, Mészáros T, Őrfi E, et al. Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: benefits of slow infusion. Nanomedicine. 2021;34:102366.
   PubMed Web of Science ®Google Scholar
• Fülöp T, Mészáros T, Kozma GT et al, Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H. Antibodies. 2018; 7(1):14.
   Web of Science ®Google Scholar
• Kozma GT, Mészáros T, Weiszhár Z, et al. Variable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: a pilot study. 2015;7:289–301.
   Google Scholar
• Pichler WJ. Adverse side-effects to biological agents. Allergy Eur J Allergy Clin Immunol. 2006;61:912–920.
   Google Scholar
• Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunol USA. 2013;2:e26333.
   PubMed Web of Science ®Google Scholar
• Hausmann O, Schnyder B, Pichler WJ. Etiology and pathogenesis of adverse drug reactions. Chem Immunol Allergy. 2012;97:32–46.
   PubMedGoogle Scholar
• Bavbek S, Ataman S, Akinci A, et al. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and Adalimumab in 12 patients. J Allergy Clin Immunol Pract USA. 2015;3:629–632.
   PubMed Web of Science ®Google Scholar
• Limb SL, Starke PR, Lee CE, et al. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120:1378–1381.
   PubMed Web of Science ®Google Scholar
• Bendele A, Colloton M, Vrkljan M, et al. Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications. J Lab Clin Med. 1995;125:493–500.
   PubMed Web of Science ®Google Scholar
• Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. Biol Treat Pediatr Inflamm Bowel Dis Decad JPGN Contrib. 2014;38(5):502–508.
   Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51–58.
   PubMed Web of Science ®Google Scholar
• Matucci A, Pratesi S, Petroni G, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43:659–664.
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. The Journal of Allergy and Clinical Immunology. 2016;137:1674–1680.
   PubMed Web of Science ®Google Scholar
• González-López MA, Martínez-Taboada VM, González-Vela MC, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007;32:672–674.
   PubMed Web of Science ®Google Scholar
• Soyer O, Demir S, Bilginer Y, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr allergy immunol. 2019;30(8):833–840.
   PubMed Web of Science ®Google Scholar
• Matucci A, Nencini F, Maggi E, et al. Hypersensitivity reactions to biologics used in rheumatology. Expert Rev Clin Immunol. 2019;15:1263–1271.
   PubMed Web of Science ®Google Scholar
• Lowndes S, Darby A, Mead G, et al. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol Off J Eur Soc Med Oncol. 2002;13:1948–1950.
   PubMed Web of Science ®Google Scholar
• Lin W-L, Lin W-C, Yang J-Y, et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2779–2780.
   PubMed Web of Science ®Google Scholar
• Bavbek S, Pagani M, Alvarez-Cuesta E, et al. Hypersensitivity reactions to biologicals: an EAACI position paper. Allergy. 2022;77:39–54.
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, et al. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019;7:618–632.
   PubMed Web of Science ®Google Scholar
• Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int. 2020;29:97–125.
   PubMedGoogle Scholar
• Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI drug allergy interest group position paper. Allergy. 2013;68:702–712.
   PubMed Web of Science ®Google Scholar
• Saretta F, Mori F, Cardinale F, et al. Pediatric drug hypersensitivity: which diagnostic tests? Acta Biomed. 2019;90:94–107.
   PubMedGoogle Scholar
• Heinzerling L, Mari A, Bergmann K-C, et al. The skin prick test-European standards. Clin Transl Allergy. 2013;3:3.
   PubMedGoogle Scholar
• Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol. 2020;11:572863.
   PubMed Web of Science ®Google Scholar
• Barbaud A, Weinborn M, Garvey LH, et al. Intradermal tests with drugs: an approach to standardization. Front Med. 2020;7:1–8.
   Web of Science ®Google Scholar
• Gomes ER, Brockow K, Kuyucu S, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI drug allergy interest group. Allergy. 2016;71:149–161.
   PubMed Web of Science ®Google Scholar
• Piva E, Chieco-Bianchi F, Krajcar V, et al. Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: in vitro evaluation of rituximab hypersensitivity by basophil activation test. Am J Hematol. 2012;87:E130–E131.
   PubMed Web of Science ®Google Scholar
• Nencini F, Vultaggio A, Pratesi S, et al. The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders. J Allergy Clin Immunol Pract. 2018;6:2065–2072.e2.
   PubMed Web of Science ®Google Scholar
• Manso L, Polo B, Fernández-Nieto M, et al. Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-alpha agent (Adalimumab). J Investig Allergol Clin Immunol. 2010;20:537–538.
   PubMed Web of Science ®Google Scholar
• Laguna JJ, Archilla J, Doña I, et al. Practical guidelines for perioperative hypersensitivity reactions. J Invest Allergol Clin Immunol. 2018;28:216–232.
   PubMed Web of Science ®Google Scholar
• Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371–376.
   PubMed Web of Science ®Google Scholar
• Silver J, Garcia-Neuer M, Lynch DM, et al. Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin. J Allergy Clin Immunol Pract. 2020;8:1668–1680e2.
   PubMed Web of Science ®Google Scholar
• Jakubovic BD, Sanchez-Sanchez S, Hamadi S, et al. Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association. Allergy. 2021;76(5):1571–1573.
   PubMed Web of Science ®Google Scholar
• Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2000;30:1144–1150.
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Vazquez-Revuelta P, Marti-Garrido J, et al. Importance of diagnostics prior to desensitization in new drug hypersensitivity: chemotherapeutics and biologicals. Curr Treat Options Allergy. 2020;7:1–13.
   Google Scholar
• Caffarelli C, Franceschini F, Caimmi D, et al. SIAIP position paper: provocation challenge to antibiotics and non-steroidal anti-inflammatory drugs in children. Ital J Pediatr. 2018;44:147.
   PubMed Web of Science ®Google Scholar
• Sancho-Serra M. D. C., Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol. 2011;41:1004–1013.
   PubMed Web of Science ®Google Scholar
• de Las Vecillas Sánchez LA, Alenazy LA, Garcia-Neuer M, et al. Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. Int J Mol Sci. 2017;18:1316.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Bormioli S, et al. Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis. Sci Rep. 2021;11:1–9.
   PubMed Web of Science ®Google Scholar
• Diaferio L, Giovannini M, Clark E, et al. Protocols for drug allergy desensitization in children. Expert Rev Clin Immunol. 2020;16:91–100.
   PubMed Web of Science ®Google Scholar
• Caimmi SME, Caimmi D, MG RS. A new pediatric protocol for rapid desensitization to monoclonal antibodies. Int Arch Allergy Immunol. 2014;165:214–218.
   PubMed Web of Science ®Google Scholar
• Jönsson F, De Chaisemartin L, Granger V, et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med. 2019;11(500):eaat1479.
   Web of Science ®Google Scholar
• Dilley MA, Lee JP, Platt CD, et al. Rituximab desensitization in pediatric patients: results of a case series. Pediatr Allergy Immunol Pulmonol. 2016;29:91–94.
   PubMed Web of Science ®Google Scholar
• Hong DI, Madrigal-Burgaleta R, Banerji A, et al. Controversies in allergy: chemotherapy reactions, desensitize, or delabel? J Allergy Clin Immunol Pract. 2020;8:2907–2915.e1.
   PubMed Web of Science ®Google Scholar
• Demir S, Soyer O, Bilginer Y, Sag E, Sahiner UM, Buyuktiryaki B, Sekerel BE, Ozen S. Desensitisation overcomes rituximab- and tocilizumab-related immediate hypersensitivity in childhood. Clin Exp Rheumatol. 2020;38(3):552-557.
   Google Scholar